Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
- Conditions
- First Posted Date
- 2001-04-30
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 40
- Registration Number
- NCT00015665
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.